English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Identifying targets for autoantibodies in CNS inflammation: Strategies and achievements

MPS-Authors
/persons/resource/persons38991

Meinl,  E.
Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society;

/persons/resource/persons38800

Derfuss,  T.
Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society;

/persons/resource/persons38969

Linington,  C.
Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society;

External Ressource
No external resources are shared
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Meinl, E., Derfuss, T., & Linington, C. (2010). Identifying targets for autoantibodies in CNS inflammation: Strategies and achievements. Clinical and Experimental Neuroimmunology, 1(2), 47-60.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0012-2017-8
Abstract
B cells and antibodies are increasingly recognized as an important feature in a broad variety of autoimmune and infectious central nervous system (CNS) diseases, such as multiple sclerosis, neuromyelitis optica, paraneoplastic diseases, acute demyelinating encephalomyelitis, Sydenham chorea, stiff-person syndrome and channelopathies. Autoantibodies might serve as a biomarker to identify the disease entity. Beyond this, autoantibodies can be a relevant pathogenic component. The present review focuses on strategies applied to identify the targets of autoantibodies and to test their pathogenetic relevance. The pathways of autoantibodies into and out of the CNS are summarized and the issue whether pathogenicity requires recognition of an extracellular target is discussed.